CG
ARIA

Caprock Group’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Caprock Group’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-11,365
Closed -$156K – 418
2016
Q3 		$156K Buy
+11,365
New +$114K 0.04% 341

Other funds holding ARIA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Caprock Group's ARIA Position: Q4 2016 in Review

Caprock Group sold out of Ariad Pharmaceuticals Inc (ARIA) in Q4 2016, closing a stake of 11,365 shares — an estimated $156K sold.

Caprock Group first reported a position in ARIA in Q3 2016 and held it in 1 quarter. The position peaked at $156K in Q3 2016. 200 funds tracked by Wall St. Rank hold ARIA as of Q4 2016.

  • Caprock Group reported no remaining Ariad Pharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
  • Caprock Group sold 11,365 Ariad Pharmaceuticals Inc shares in Q4 2016, an estimated $156K.
  • Caprock Group first reported a position in Ariad Pharmaceuticals Inc in Q3 2016 and held it in 1 quarter.
  • Caprock Group's Ariad Pharmaceuticals Inc position peaked at $156K in Q3 2016.
  • 200 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q4 2016.

Based on Caprock Group's 13F filing for Q4 2016, filed 24 Jan 2017.